Swiss biotech Polyphor has seen its key cancer asset balixafortide fail a late-stage trial, leaving its future in the balance. That trial, a phase 3 test know as Fortress, was studying Polyphor’s GPCR-derived med balixafortide in more than 400 patients with …
See Original Article

By submitting my information, I agree to the Privacy Policy and Terms of Service and to receive offers and promotions from Bloomberg. Bitcoin pushed
See Original Article

Key players in Global Financial Accounting System Market include: Intuit, Sage, SAP, Oracle (NetSuite), Microsoft, Infor, Epicor, Workday, Unit4, Xero,
See Original Article

Honda and GM have been partners on hydrogen fuel cell and electric vehicles. Earlier this year they announced that GM would build one Honda SUV and one Acura SUV using its Ultium-branded electric vehicle architecture and battery system.
See Original Article

Payrolls may have risen by 700,000 in June, according to the median estimate in a Bloomberg survey of economists. That would be the biggest
See Original Article